Immunomedics, Inc. (IMMU)
(Delayed Data from NSDQ)
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IMMU) Outperforming Other Medical Stocks This Year?
Immunomedics' Shares Rise on Positive Breast Cancer Drug Data
by Zacks Equity Research
Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.
Immunomedics' Shares Surge YTD on Cancer Drug Approval
by Zacks Equity Research
Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.
Immunomedics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Immunomedics.
Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IMMU) Outperforming Other Medical Stocks This Year?
Why Is Immunomedics (IMMU) Down 6.6% Since Last Earnings Report?
by Zacks Equity Research
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IMMU) Outperforming Other Medical Stocks This Year?
Is Immunomedics (IMMU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (IMMU) Outperforming Other Medical Stocks This Year?
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.
BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year.
Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus
by Zacks Equity Research
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.
Immunomedics, Inc. (IMMU) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Immunomedics, Inc. (IMMU).
Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil
by Zacks Equity Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
Why Immunomedics (IMMU) Might Surprise This Earnings Season
by Zacks Equity Research
Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Hanger (HNGR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger's (HNGR) first-quarter 2020 results are likely to reflect strong performance at its Patient Care segment, partially offset by high costs.
Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.
First-Mover Pandemic Disease Fight ETF On The Way
by Sweta Killa
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Immunomedics Wins Fast FDA Approval for Breast Cancer Drug
by Zacks Equity Research
The FDA nods to Immunomedics' (IMMU) Trodelvy for treating patients with metastatic triple-negative breast cancer, having previously received minimum two therapies. Stock rallies in pre-market trading.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
by Zacks Equity Research
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).